CYG
NBSE

Clean Yield Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Clean Yield Group’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-155
Closed -$15K – 487
2021
Q2 		$15K Buy
+155
New +$17.1K 0.01% 340
2021
Q1 		– Sell
-155
Closed -$22K – 404
2020
Q4 		$22K Buy
+155
New +$25.1K 0.01% 309

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clean Yield Group's NBSE Position: Q3 2021 in Review

Clean Yield Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2021, closing a stake of 155 shares — an estimated $15K sold.

Clean Yield Group first reported a position in NBSE in Q4 2020 and held it in 2 quarters. The position peaked at $22K in Q4 2020. 47 funds tracked by Wall St. Rank hold NBSE as of Q3 2021.

  • Clean Yield Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Clean Yield Group sold 155 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $15K.
  • Clean Yield Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Clean Yield Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $22K in Q4 2020.
  • 47 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Clean Yield Group's 13F filing for Q3 2021, filed 27 Oct 2021.